Loading...
•
Jun 30, 2021
Caribou Biosciences Q2 2021 Earnings Report
Reported business highlights and financial results for the second quarter of 2021.
Key Takeaways
Caribou Biosciences reported a net loss of $14.3 million for the second quarter of 2021. The company completed an upsized IPO raising $349.6 million in gross proceeds and dosed the first patient in Phase 1 clinical trial of CB-010.
Dosed the first patient in Phase 1 clinical trial of CB-010.
Completed upsized IPO raising $349.6 million in gross proceeds.
Expanded Caribou’s board of directors with appointment of Nancy Whiting, Pharm.D.
Published data demonstrating the significantly improved specificity of Caribou’s proprietary CRISPR hybrid RNA-DNA (chRDNA) guide technology compared to all-RNA guides.
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences Revenue by Segment
Revenue by Segment
Licensing and collaboration Revenue
CapyFin.com Forward Guidance
Caribou expects initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL in 2022. Caribou expects to file an Investigational New Drug (IND) application for its CB-011 program in 2022. Caribou expects to file an IND application for its CB-012 program in 2023. Caribou expects to announce target selection for its CB-020 program in 2022.
Positive Outlook
- Initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL is expected in 2022.
- An Investigational New Drug (IND) application for its CB-011 program is expected to be filed in 2022.
- An IND application for its CB-012 program is expected to be filed in 2023.
- Target selection for its CB-020 program is expected to be announced in 2022.
- CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells engineered using Cas9 chRDNA technology.
Challenges Ahead
- Risks inherent in drug development
- Risks associated with the initiation, cost, timing, progress and results of current and future research and development programs
- Risks associated with preclinical studies
- Risks associated with clinical trials
- Uncertainties in forward-looking statements